Survival in dogs with nasal adenocarcinoma: 64 cases (1981-1995).
Case records of 64 dogs with nasal adenocarcinoma were reviewed. The effects of age, gender, tumor stage, presence of metastatic lesions, and treatment method on survival time were examined. Surgery groups included rhinotomy (n = 9), transnasal curettage (n = 29), and no surgery (n = 26). Chemotherapy groups included fluorouracil-cyclophosphamide combination therapy (n = 15), mitoxantrone (n = 7), and no chemotherapy (n = 42). Fifty-three dogs received fractionated cobalt 60 radiation therapy. Surgical procedure, chemotherapy group, and stage of primary tumor were not significantly associated with survival time (P > .05). Dogs that received radiation therapy had a significantly longer median survival time (424 days) than dogs that did not (126 days)(P = .0001). The presence of either regional lymph node or pulmonary metastasis was associated with significantly shorter median survival time (109 days) when compared to dogs without metastases (393 days)(P = .0125). When only dogs that had received radiation therapy were considered, neither surgical treatment nor chemotherapy group was associated with significant changes in median survival time. An alternate staging system emphasizing the presence or absence of metastases is proposed.
Henry
C J
CJ
Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia 65211, USA. chenry@vets.vetmed.missouri.edu
Brewer
W G
WG
Tyler
J W
JW
Brawner
W R
WR
Henderson
R A
RA
Hankes
G H
GH
Royer
N
N
D000230:Adenocarcinoma / Q000401:mortality / Q000628:therapy / Q000662:veterinary*; D000367:Age Factors; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004283:Dog Diseases / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D004285:Dogs; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D008297:Male; D008942:Mitoxantrone / Q000627:therapeutic use; D009367:Neoplasm Staging / Q000662:veterinary; D009669:Nose Neoplasms / Q000401:mortality / Q000628:therapy / Q000662:veterinary*; D011379:Prognosis; D012189:Retrospective Studies; D012737:Sex Factors; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D003037:Cobalt Radioisotopes; D003520:Cyclophosphamide; D008942:Mitoxantrone; D005472:Fluorouracil